The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
Open accessAbstract
BACKGROUND: The outcomes of patients with surgery- and radiation-refractory meningiomas treated with medical therapies are poorly defined. Published reports are limited by small patient numbers, selection bias, inclusion of mixed histologic grades and stages of illness, and World Health Organization (WHO) criteria changes. This analysis seeks to define outcome benchmarks for future clinical trial design. METHODS: A PubMed literature search was performed for all English language publications on medical therapy for meningioma. Reports were tabulated and analyzed for number of patients, histologic grade, prior therapy, overall survival, progression-free survival (PFS), and radiographic response. RESULTS: Forty-seven publications were identified and divided by histology and prior therapies, including only those that treated patients who were surgery and radiation refractory for further analysis. This included a variety of agents (hydroxyurea, temozolomide, irinotecan, interferon-α, mifepristone, octreotide analogues, megestrol acetate, bevacizumab, imatinib, erlotinib, and gefitinib) from retrospective, pilot, and phase II studies, exploratory arms of other studies, and a single phase III study. The only outcome extractable from all studies was the PFS 6-month rate, and a weighted average was calculated separately for WHO grade I meningioma and combined WHO grade II/III meningioma. For WHO I meningioma, the weighted average PFS-6 was 29% (95% confidence interval [CI]: 20.3%-37.7%). For WHO II/III meningioma, the weighted average PFS-6 was 26% (95% CI: 19.3%-32.7%). CONCLUSIONS: This comprehensive review confirms the poor outcomes of medical therapy for surgery- and radiation-refractory meningioma. We recommend the above PFS-6 benchmarks for future trial design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Travis, W. D., Castile, R., Vawter, G., Shwachman, H., Warwick, W., Burke, B. A., & Skinner, M. (1986) · American Journal of Clinical Pathology · doi:10.1093/ajcp/85.4.419 · Cited by 1,189
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Self-citationTreatment of unresectable meningiomas with the antiprogesterone agent mifepristone
Grunberg, S. M., Weiss, M. H., Spitz, I. M., Ahmadi, J., Sadun, A., Russell, C. A., Lucci, L., & Stevenson, L. L. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.74.6.0861 · Cited by 379
DEATH DURING THERAPEUTIC STARVATION
Hermann, L. S., & Iversen, M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92649-4 · Cited by 361
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Kaley, T. J., Wen, P., Schiff, D., Ligon, K., Haidar, S., Karimi, S., Lassman, A. B., Nolan, C. P., DeAngelis, L. M., Gavrilovic, I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou148 · Cited by 294
Self-citationBevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
Lou, E., Sumrall, A. L., Turner, S., Peters, K. B., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Herndon, J. E., McSherry, F., Norfleet, J., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0861-0 · Cited by 196
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Norden, A. D., Raizer, J. J., Abrey, L. E., Lamborn, K. R., Lassman, A. B., Chang, S. M., Yung, W. K. A., Gilbert, M. R., Fine, H. A., Mehta, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9948-7 · Cited by 196
Self-citation
Cited by
EANO guidelines for the diagnosis and treatment of meningiomas
Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30321-7 · Cited by 854
Response Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 435
Self-citationOncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Abedalthagafi, M., Bi, W. L., Aizer, A. A., Merrill, P. H., Brewster, R., Agarwalla, P. K., Listewnik, M. L., Dias-Santagata, D., Thorner, A. R., Van Hummelen, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov316 · Cited by 293
Self-citation
Metadata
- Authors
- Kaley, T., Barani, I., Chamberlain, M., McDermott, M., Panageas, K., Raizer, J., Rogers, L., Schiff, D., Vogelbaum, M., Weber, D., & Wen, P.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-04
- Volume
- 16
- Issue
- 6
- Pages
- 829-840
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W1988927456
- Cited by
- 270
- References
- 27
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. https://app.cochat.ai/papers/10.1093/neuonc/not330
- The paper
- Kaley, T., Barani, I., Chamberlain, M., McDermott, M., Panageas, K., Raizer, J., Rogers, L., Schiff, D., Vogelbaum, M., Weber, D., & Wen, P. (2014). Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology. https://doi.org/10.1093/neuonc/not330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
